Compare SOTK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | ACET |
|---|---|---|
| Founded | 1975 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 83.3M |
| IPO Year | 1995 | 2017 |
| Metric | SOTK | ACET |
|---|---|---|
| Price | $4.95 | $9.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | 28.8K | ★ 80.5K |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $20,909,315.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $99.79 | ★ N/A |
| Revenue Growth | ★ 1.97 | N/A |
| 52 Week Low | $3.40 | $0.46 |
| 52 Week High | $6.24 | $9.84 |
| Indicator | SOTK | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 44.59 | 57.58 |
| Support Level | $4.83 | $7.45 |
| Resistance Level | $5.72 | $9.59 |
| Average True Range (ATR) | 0.29 | 0.53 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 15.63 | 73.95 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).